If approved, momelotinib will slide into GSK portfolio alongside Blenrep (belantamab mafodotin), its BCMA-targeting antibody-drug conjugate, which was approved in 2020 as a therapy for multiple ...

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

Meanwhile, with the EMA now formally starting its review of momelotinib, GSK could be in a position to get approval for the drug in late 2023/early 2024 in the EU, a few months after the FDA is ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

[17] Dr. Stephanie Ambrose, GSK Singapore Medical Director, said: "We note that myelofibrosis is a complex disease and there are significant challenges in the management of the disease ...

[17] This highlights an unmet need for effective treatments for myelofibrosis patients with anaemia. [17] Dr. Stephanie Ambrose, GSK Singapore Medical Director, said: "We note that myelofibrosis is a ...